Payment overview · 2025
General Payments
$277.00
18 reported records · 8 companies
Healthcare provider profile · identity verified
Timothy J Luithle, MD
Allopathic & Osteopathic Physicians|Family Medicine · HILLSBORO, ND · NPI 1578581146
Verified facts
What the public records show
CMS Open Payments records show Timothy J Luithle, MD received $277.00 in general payments during 2025 across 18 reported records.
Novo Nordisk Inc accounted for 23.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $66.24 | 23.9% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $58.13 | 21.0% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $50.05 | 18.1% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.50 | 12.1% | 4 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $23.16 | 8.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.92 | 6.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.69 | 5.3% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $14.31 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $277.00 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $58.13 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $48.27 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $33.50 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $30.92 | 2 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $28.55 | 1 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.92 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.92 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $16.92 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $16.92 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $14.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Furosemide | Furosemide | 372 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 333 | 64 |
| Omeprazole | Omeprazole | 318 | 60 |
| Levothyroxine Sodium | Levothyroxine Sodium | 284 | 46 |
| Atorvastatin Calcium | Atorvastatin Calcium | 283 | 64 |
| Losartan Potassium | Losartan Potassium | 232 | 49 |
| Lisinopril | Lisinopril | 231 | 54 |
| Simvastatin | Simvastatin | 225 | 45 |
| Sertraline Hcl | Sertraline Hcl | 203 | 31 |
| Amlodipine Besylate | Amlodipine Besylate | 202 | 42 |
| Tramadol Hcl | Tramadol Hcl | 182 | 39 |
| Gabapentin | Gabapentin | 174 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 166 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 162 | 32 |
| Metformin Hcl | Metformin Hcl | 159 | 34 |
| Alprazolam | Alprazolam | 153 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 152 | 22 |
| Trazodone Hcl | Trazodone Hcl | 151 | 26 |
| Eliquis | Apixaban | 148 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 133 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 127 | 20 |
| Mirtazapine | Mirtazapine | 126 | 20 |
| Warfarin Sodium | Warfarin Sodium | 126 | 15 |
| Potassium Chloride | Potassium Chloride | 122 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 118 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 110 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 93 | 17 |
| Jardiance | Empagliflozin | 92 | suppressed |
| Lorazepam | Lorazepam | 90 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 87 | 11 |
| Donepezil Hcl | Donepezil Hcl | 86 | 17 |
| Meloxicam | Meloxicam | 79 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 78 | 11 |
| Allopurinol | Allopurinol | 72 | 13 |
| Carvedilol | Carvedilol | 64 | 12 |
| Famotidine | Famotidine | 63 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 14 |
| Montelukast Sodium | Montelukast Sodium | 60 | 17 |
| Bupropion Xl | Bupropion Hcl | 56 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 55 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 12 |
| Metformin Hcl Er | Metformin Hcl | 53 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 52 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 12 |
| Pregabalin | Pregabalin | 48 | 12 |
| Buspirone Hcl | Buspirone Hcl | 47 | suppressed |
| Myrbetriq | Mirabegron | 47 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 36 |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 45 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | suppressed |
| Spironolactone | Spironolactone | 45 | suppressed |
| Celecoxib | Celecoxib | 44 | suppressed |
| Olanzapine | Olanzapine | 43 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 19 |
| Finasteride | Finasteride | 41 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | suppressed |
| Clonazepam | Clonazepam | 40 | suppressed |
| Prednisone | Prednisone | 40 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 39 | suppressed |
| Ezetimibe | Ezetimibe | 39 | suppressed |
| Atenolol | Atenolol | 38 | suppressed |
| Latanoprost | Latanoprost | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 38 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Glipizide Er | Glipizide | 34 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 33 | suppressed |
| Estradiol | Estradiol | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Novolog Flexpen | Insulin Aspart | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Carbamazepine Er | Carbamazepine | 28 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Calcitriol | Calcitriol | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 20 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 24 | suppressed |
| Combipatch | Estradiol/Norethindrone Acet | 23 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 20 |
| Azithromycin | Azithromycin | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 14 |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 14 | suppressed |
| Methadone Hcl | Methadone Hcl | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Cholestyramine Light | Cholestyramine | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
| Pentips Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Savella | Milnacipran Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $277.00 · 18 records | Novo Nordisk Inc | CAPLYTA, CAPVAXIVE, GARDASIL 9, General - Pain Management, LEQVIO, MONOFERRIC, Ozempic, Rybelsus, VAXELIS, VAXNEUVANCE, VOQUEZNA, WaveWriter Alpha Prime 16, Wegovy, YUPELRI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error